Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
ESMO Open|December 2, 2020
Management of patients with early-stage colon cancer: guidelines of the Italian Medical Oncology AssociationLisa Salvatore, Marco Imperatori, Ermenegildo Arnoldi, et al.
The Oncologist|April 13, 2013
A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinomaLorenza Rimassa, Tiziana Pressiani, Corrado Boni, et al.
Cancer Medicine|February 15, 2026
Real-World Experience of Efficacy and Tolerability of Continuous Infusion Ifosfamide for Advanced Soft Tissue and Bone Sarcoma Patients: A Single Centre Retrospective CohortIlaria Mascagni, Alice Laffi, Maria Susanna Grimaudo, et al.
European Journal of Cancer (Oxford, England : 1990)|August 17, 2010
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapyArmando Santoro, Lorenza Rimassa, Alberto F Sobrero, et al.
Exploration of Targeted Anti-Tumor Therapy|July 28, 2025
Correlation between histopathological features and recurrence score according to menopausal status in HR+/HER2- breast cancer patients: a retrospective studyFederica Martorana, Sabrina Nucera, Gianmarco Motta, et al.
Neuroendocrinology|May 30, 2017
Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown PrimarySimron Singh, Carlo Carnaghi, Roberto Buzzoni, et al.
Lancet (London, England)|December 26, 2015
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 studyJames C Yao, Nicola Fazio, Simron Singh, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|January 24, 2018
Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world studyMaria Rinzivillo, Nicola Fazio, Sara Pusceddu, et al.
The Lancet. Oncology|August 26, 2017
Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialMarianne E Pavel, Simron Singh, Jonathan R Strosberg, et al.
Journal of the National Cancer Institute|April 19, 2007
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trialStefano Cascinu, Roberto Labianca, Carlo Barone, et al.
Pageof 7